Achaogen, which is developing antibacterials for the treatment of multi-drug resistant infections, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The South San Francisco, CA-based company, which was founded in 2002 and booked $16 million in grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol AKAO. Credit Suisse and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
